Labiotech.eu

News and Trends 6 May 2015

Hello Tomorrow Challenge, a preview of the startup competition

Hello Tomorrow’s main goal is to create bridges between scientists, investors and entrepreneurs in all major technological fields. On 9th of April 2015, the team of Hello Tomorrow invited us to attend to their press conference given at the Ministry of Foreign Affairs in Paris. In April 2014, after three long years of preparation, the “First day […]

May 6, 2015 - 3 minutesmins - By Joachim Eeckhout

thrombosis bayer healthcare isis pharmaceuticals

News and Trends 5 May 2015

Isis Pharmaceuticals and Bayer HealthCare team up to prevent thrombosis

Isis Pharmaceuticals and Bayer HealthCare will develop and commercialize ISIS-FXIRx for the prevention of thrombosis. The German Pharma will provide up to €139M to Isis, including an up-front payment of €89.6M. Under the terms of the agreement, Isis is eligible to receive up to €139M in near-term payments, including an immediate €89.6M up-front payment and […]

May 5, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 May 2015

Natural Killer therapies for Cancer: a Fast-Evolving field

Natural killers are an emerging approach to fight inflammatory diseases and cancer. These immune actors, that specifically regulate the activity of the immune system, are attracting the attention of several small startups and more than a few big Pharmas. The immune system includes a set of body defenses, that fight foreign forms. But external bodies aren’t […]

May 5, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 4 May 2015

Karolinska Development took a Step Back in its Biotech portfolio

The finances of Karolinska Development remain in a dangerous downward spiral as the company dropped to €136.9M (SEK 1,277 million), an unsatisfactory record for the company, the lowest valuation since 2011. For this purpose, the company decided to totally abandon investing in Pergamum, Umecrine and NeoDynamics AB, three biotech companies. Karolinska’s reaction is well-defined: the […]

May 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 May 2015

Sygnis on the way to conquer the UK Life Sciences market

Sygnis signed a distribution agreement with Cambridge Bioscience for the commercialization of its proprietary product portfolio in the UK and Ireland. This is a significant expansion of product roll-out into one of the most important life science markets in Europe. Under the terms and conditions of the agreement, Cambridge Bioscience will promote, market, sell and […]

May 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 3 May 2015

After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug

Poxel continues to interest the market after its successful IPO in February 2015, where it has raised approximately €27M with an incredible jump of +100% on its third day as a public company. Imeglimin, its lead candidate, is a Type 2 diabetes treatment (licensed by Merck Serono) on the launch of Phase III. This innovative compound is […]

May 3, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 2 May 2015

Newron raised new funds to continue the development of Neurological therapies

Newron Pharmaceuticals, a public company focused on novel Central Nervous System (CNS) and pain therapies, announces that it has completed a capital increase of approximately €23.2M (CHF24.3 million). This fundraising will be used to accelerate the development of Newron’s pipeline of innovative CNS therapeutics: The company priority seems to be on NW-3509, an add-on therapy for schizophrenia, for […]

May 2, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 2 May 2015

PlugMed has Just Won €2M Funding to Develop an Innovative Device against Kidney Failure

PlugMed has been awarded €2 million of funding, as part of the World Innovation Challenge organized by the French Ministry of Industry. It will enable the company to speed up the Geroneph project that aims at developing an innovative device in the treatment of kidney failure. Nowadays, dialysis is used by more than two million people […]

May 2, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 1 May 2015

Galderma steps into the Nutraceutical Market

Galderma entered the functional food market thanks to its acquisition of certain assets of Innéov Group. The company, a global leader committed to dermatology and skin health, is fully-owned by Nestlé Skin Health. On April 24th Nestlé Skin Health announced that Galderma, its company focused on medical solutions, has come to an agreement under which it […]

May 1, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 1 May 2015

Addex Therapeutics: When one of the leading Swiss Biotech startups relives

Biotech startups are risky. They need lot of cash to come across the very regulated clinical path and can fail rapidly when bad results show up. Addex Therapeutics, a Swiss Geneva-based Biotech company, has raised more than €200M throughout its existence and signed deals worth more than €1Bn with Merck and J&J. Yet, on the 31st May 2013, the company almost […]

May 1, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 30 Apr 2015

Gene-editing Technology war continues while CRISPR Therapeutics raised €79.5M

As the CRISPR-Cas9 war still goes on, CRISPR Therapeutics closed a Series A and B financing round with €79.5M. The oversubscribed financing rounds were led by strategic investors, GlaxoSmithKline‘s SR One and Celgene Corporation, respectively and also included other actors already known by the company, such as Versant Ventures, along with new ones namely New […]

April 30, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 30 Apr 2015

A new Microfluidic Chip technology raised €1.9Million

Lunaphore Technologies closed a Series A financing round of €1.9M (CHF 2 millions). The round was led by Redalpine Venture Partners in Zurich with the participation of private investors from Switzerland and the United Kingdom. Lunaphore’s young team wants to use this cash to develop its first tissue diagnostics platform. The young Swiss medtech company, […]

April 30, 2015 - 3 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Hello Tomorrow Challenge, a preview of the startup competition

Isis Pharmaceuticals and Bayer HealthCare team up to prevent thrombosis

Natural Killer therapies for Cancer: a Fast-Evolving field

Karolinska Development took a Step Back in its Biotech portfolio

Sygnis on the way to conquer the UK Life Sciences market

After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug

Newron raised new funds to continue the development of Neurological therapies

PlugMed has Just Won €2M Funding to Develop an Innovative Device against Kidney Failure

Galderma steps into the Nutraceutical Market

Addex Therapeutics: When one of the leading Swiss Biotech startups relives

Gene-editing Technology war continues while CRISPR Therapeutics raised €79.5M

A new Microfluidic Chip technology raised €1.9Million

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!